Go Pro
NASDAQ:HYFT

MindWalk Q3 2026 Earnings Report

MindWalk logo
$1.42 +0.04 (+2.90%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$1.42 +0.00 (+0.28%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MindWalk EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

MindWalk Revenue Results

Actual Revenue
$3.00 million
Expected Revenue
$3.50 million
Beat/Miss
Missed by -$500.00 thousand
YoY Revenue Growth
N/A

MindWalk Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

MindWalk Earnings Headlines

A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.tc pixel
MindWalk (NASDAQ:HYFT) Stock Rating Upgraded by Wall Street Zen
AI Found an Influenza Target That Survives Viral Mutation
See More MindWalk Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MindWalk? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MindWalk and other key companies, straight to your email.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

View MindWalk Profile